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 2 
Abstract 29 
The inflammatory response to acute myocardial ischaemia/reperfusion injury (IRI) plays a critical 30 
role in determining myocardial infarct (MI) size and subsequent post-MI left ventricular (LV) 31 
remodeling, making it a potential therapeutic target for treating patients presenting with an acute 32 
myocardial infarction (AMI). Recent experimental studies using advanced imaging and molecular 33 
techniques have yielded new insights into the mechanisms through which reactive oxygen species 34 
(ROS) contribute to the inflammatory response during acute myocardial IRI - “adding fuel to the 35 
fire”. The infiltration of inflammatory cells into the MI zone, leads to elevated myocardial 36 
concentrations of ROS, cytokine release, and activation of apoptotic and necrotic death pathways. 37 
Anti-oxidant and anti-inflammatory therapies have failed to protect the heart against acute 38 
myocardial IRI. This may be, in part, to a lack of understanding of the time course, nature and 39 
mechanisms of the inflammation and redox dysregulation which occur in the setting of acute 40 
myocardial IRI. In this article, we will examine the inflammatory response and redox dysregulation 41 
induced by acute myocardial IRI, and highlight potential therapeutic options for targeting redox 42 
dysregulation in order to attenuate the detrimental effects of the inflammatory response following an 43 
AMI so as to reduce MI size and prevent heart failure. 44 
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1. Introduction 85 
Acute myocardial infarction (AMI) and the heart failure which often ensues are one of the leading 86 
causes of death and disability worldwide. For patients presenting with an AMI, the treatment of 87 
choice is to restore coronary blood flow in the infarct-related artery, to salvage viable myocardium. 88 
However, despite optimal therapy the morbidity and mortality of AMI patients remain significant with 89 
7% death and 25% heart failure at one year [1]. The reason for this, is in part, due to the presence 90 
of ‘myocardial reperfusion injury’ which refers to the myocardial injury and cardiomyocyte death, 91 
that is paradoxically induced by myocardial reperfusion, and which can contribute up to 50% of the 92 
final myocardial infarct (MI) size, and for which, there is currently no effective therapy [2] [3]. As 93 
such, novel therapies are required to protect the heart against acute myocardial 94 
ischaemia/reperfusion injury (IRI), in order to reduce MI size and prevent heart failure. 95 
 The inflammatory response to acute myocardial IRI plays a critical role in determining MI 96 
size and subsequent post-MI left ventricular (LV) remodelling, making it a potential therapeutic 97 
target for preventing heart failure following AMI. Experimental studies using molecular techniques 98 
and advanced biomedical imaging have yielded new insights into the mechanisms through which 99 
reactive oxygen species (ROS) contribute to the inflammatory response during acute myocardial 100 
IRI, “adding fuel to the fire”. The infiltration of inflammatory cells into the MI zone, leads to elevated 101 
concentrations of ROS in the myocardium, cytokine release, and the activation of apoptotic and 102 
necrotic death pathways. The complex interplay between ROS and inflammation can amplify the 103 
effects of ROS as mediators of myocardial injury and determinants of cell death. As such, ROS 104 
represent important therapeutic targets for reducing MI size and preventing adverse LV remodelling 105 
in AMI patients. In this review article, we highlight the complex interplay between ROS and 106 
inflammation in the setting of acute myocardial IRI, and explore emerging therapeutic targets for 107 
attenuating ROS and modulating the inflammatory response in patients presenting with AMI. 108 
 109 
2. Oxygen Paradox and ROS formation 110 
When the myocardium is re-oxygenated after a prolonged period of energy depletion, it rapidly 111 
hypercontracts. The hypercontracture and cytolysis induced by reoxygenation have become known 112 
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as the “Oxygen Paradox” [4], [5], [2]. Bresnahan et al. [6], demonstrated in a canine model that the 113 
potentiation of haemorrhage and extension of myocardial infarction is attributable to the re-114 
administration of molecular oxygen. Using the isolated perfused rat heart, in 1973, Hearse and 115 
Chain showed that the reoxygenation kills the heart cells and exacerbates cardiac enzyme creatine 116 
phosphokinase (CPK), ATP, AMP phosphotransferase (MK) and glyceraldehyde-3-phosphate 117 
dehydrogenase (GAPDH) release. The myocardial injury was not identified. However the possible 118 
responsible listed was ROS overproduction [4]. 119 
 Following AMI, ROS are generated in the first minute of reperfusion, and peak 4-7 minutes 120 
later, although ROS production continues at lower sustained levels for quite some time after [7]. 121 
Oxidative stress or redox dysregulation occurs in the myocardium when ROS production is 122 
enhanced, and the anti-oxidant reserve is exhausted. This highly reactive and unstable group of 123 
compounds are formed as a result of the addition of an unpaired electron in the outer orbit of the 124 
molecule. Superoxide (O-2), hydrogen peroxide (H2O2), and the highly reactive hydroxyl radical 125 
(OH) are the most prominent free radicals in the pathogenesis of acute myocardial IRI. In the 126 
presence of iron, superoxide and H2O2 can lead to the formation of highly reactive OH, which can 127 
damage cellular proteins, RNA, DNA and lipids. Interaction of ROS with nitrogen monoxide (NO) 128 
[8] or fatty acids can produce peroxynitrite or peroxyl radicals, respectively. The first ROS produced 129 
in response to acute IRI is O-2, resulting from the univalent reduction of molecular oxygen. 130 
Dismutation of O-2 produces H2O2, which, in turn, may be entirely reduced to water or partially 131 
reduced to OH, one of the strongest pro-oxidants in nature. Also, O-2 may react with nitric oxide in 132 
a reaction controlled by the rate of diffusion of both radicals [9] [10] [11] (fig. 1). The generation of 133 
ROS has been connected to stress responses, apoptosis, aging and death. However, the ROS are 134 
now being recognized as molecules involved in the cardiac adaptation to different types of 135 
physiological stimuli [12] [13] [14] [15] [16]. 136 
 137 
3. Biological roles of ROS in the heart 138 
 6 
The most recognized ROS with physiological effects includes the O-2, NO and the non-radical 139 
specie H2O2. There have been implicated in the regulation of inflammation [17] [18] [19], calcium 140 
signaling [20], hypertrophy [21], autophagy [22] and cardioprotection [23]. 141 
Cysteine (Cys) and methionine (Met) possess reactive sulfur-containing side chains that 142 
present targets for ROS [16] [24]. Oxidation of these specific and reactive residues, in turn can, lead 143 
to the reversible modification of enzymatic activity. Four oxidation states of Cys can be generated: 144 
disulfide (-S-S), sulfenic acid (-SOH) and sulfonic acid (-SO3H) [16]. Sulfenic acid is readily reduced 145 
to cysteine by the cellular reducing agents, glutathione (GSH) and thioredoxin (Trx) [25] [26]. 146 
Methionine is oxidized to methionine sulfoxide (MetO) by the addition of an extra oxygen atom [27]. 147 
The Anderson laboratory found that following initial Ca2+-dependent activation of CaMKII 148 
(Ca2+/calmodulin-dependent kinase II), the specific oxidation of conserved Met 281/282 residues in 149 
the regulatory domain could increase CaMKII activity independent of Ca2+/calmodulin [28]. 150 
Substantial evidence has revealed that H2O2 production has been shown to be a major 151 
component of endothelium-derived hyperpolarizing factor to control blood pressure [29] [30]. H2O2 152 
also caused interprotein disulfide bond in protein kinase G (PKG) which activated the kinase 153 
independently pf the NO-cyclic guanosine monophosphate (cGMP) pathway and coupled to 154 
vasodilation [31]. In a redox-dead Cys42Ser PKGI- knock-in mouse, Prysyazhna et al., 155 
demonstrated that H2O2 inuce an oxidation and activation of PKG which cause vessel 156 
hyperpolarization and relaxation [32]. Also, the treatment of endothelial cells or aortic vessels with 157 
vascular endothelial growth factor (VEGF) induced growth signaling and angiogenesis dependent of 158 
protein kinase A (PKA) oxidation [33]. 159 
 Modulation of the redox potential of reactive thiols may be a general control mechanism by 160 
which sarcoplasmic/endoplasmic (SR/ER) reticulum and ryanodine receptor (RyR) controls 161 
cytoplasmic Ca2+ concentrations in the skeletal muscle [34] and myocardium [35]. Yi X et al., 162 
demonstrated in coronary artery smooth muscle that a local NADPH oxidase system on SR/ER 163 
regulates RyR/Ca2+ channel activity and Ca2+ release from SR/ER by producing O-2 [20]. The thiol-164 
disulfide exchange model in cardiac muscle has been proposed to describe the mechanism by 165 
which O-2 can directly activate the RYR/Ca2+. In this model, intermolecular thiol-disulfide 166 
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interexchange reaction within RyR control open or closed states of its Ca2+ release channels. When 167 
the thiol groups of RyR is in a reduced status (-SOH form), the channel is closed. In contrast, the 168 
channel is open when disulfide is formed by oxidation of thiol groups of RyR (-S-S-form) [36] [37] 169 
[38] [39]. 170 
 In vascular smooth muscle (VSM), angiotensin II increases NADPH oxidase-dependent 171 
ROS production, which is thought to activate signaling pathways involved in the hypertrophic 172 
response [40] [41]. The redox signaling modulation of the small G proteins Ras kinases such as 173 
ERK1/2, p38MAPK, protein kinase C (PKC) and Akt contribute to the development of GPCR 174 
agonist-induced hypertrophy [31] [42]. 175 
 Hydrogen peroxide can induce kinase activation via tyrosine phosphorylation or via the 176 
induction of the released zinc from zinc-finger domains of PKC [43]. It has been proposed that O-2 177 
and H2O2 may play an important signaling role in cardioprotection. Most of the signaling pathways 178 
of cardioprotection converge at the mitochondria and the mitochondrial ROS formation mediates 179 
signal transduction through post-translational modifications of redox-sensitive proteins [44] [45] [46]. 180 
Perrelli et al., demonstrated for the first time that the cardioprotective effect of catestatine as a 181 
pharmacological postconditioning (CST-Post) depends on the activation of PI3K/Akt, PKCs and 182 
mitoKATP channels, which may include a ROS signaling [23]. 183 
It may seem paradoxical that ROS are essential for promoting normal cellular processes, as 184 
opposed to having a toxic effect on the heart. Even cell death that was previously thought to result 185 
from oxidative damage is now considered to be the result of ROS triggering a physiological pathway 186 
for cell death. Maintaining a basal level of ROS which is above a cytostatic level, but below 187 
cytotoxic, therefore enables proper redox biology reactions and the regulation of numerous 188 
processes essential for life. 189 
 190 
4. Sources of ROS and the interplay with inflammation during acute myocardial IRI 191 
A number of different mechanisms and sources are known to underlie ROS generation in the 192 
myocardium in the setting of acute IRI. The enzymes systems most commonly implicated in ROS 193 
production are cytochrome P-450 (CYP), xanthine oxidase, NADPH oxidase, monoamine oxidases 194 
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(MAO), uncoupled nitric oxide synthase (NOS), the unfolded-protein response (UPR)-regulated 195 
oxidative protein folding machinery in the SR/ER, and the mitochondrial electron transport chain 196 
[47] (fig. 2A).  197 
 198 
a. Cytochrome P-450  199 
The cytochrome P-450 (CYP) family of proteins are mono-oxygenases, which catalyse the oxidation 200 
of hydrophobic organic molecules mainly in the liver, but also in the heart [48]. The CYP system is 201 
known to be a potential source of ROS following reperfusion of the acutely ischaemic myocardium, 202 
mainly from endothelial cells [49], macrophages, and neutrophils [50]. It has already been shown 203 
that ROS can arise from the decay of oxygenated CYP intermediates produced during the catalytic 204 
mechanism of mixed-function oxidation. The contents of ROS derived from cytochrome P-450 have 205 
been shown to increase in an oxygen concentration-dependent manner as CYP generates O-2 and 206 
H2O2 through an uncoupling reaction. It is conceivable that the increase in ROS produced by CYP 207 
upon reperfusion are due to an increase in uncoupling, concomitant with the increment of oxygen 208 
supply to myocardium [51]. 209 
Members of the cytochrome P-450 2-epoxygenases family (CYP 2), primarily 2C8, 2C9 and 210 
2J2, and the hydroxylase CYP 4F are capable of metabolising endogenous arachidonic acid (AA) 211 
into vasoactive products such as epoxyeicosatrienoic acids (EETs) and hydroxyeicosatetraenoic 212 
acids (HETEs). Although EETs have been reported to play a cardioprotective role, CYP 2C9 can 213 
also generate O-2, H2O2, and •OH during the CYP reaction cycle [52]. Using a rat Langendorff 214 
preparation, Granville et al., showed that CYP 2C9 is a potent source of ROS during acute 215 
myocardial IRI, and contributes to the extension of MI size [53]. The O-2 and H2O2 produced by CYP 216 
2C9 can trigger NFB activation resulting in the upregulation and secretion of pro-inflammatory 217 
cytokines and adhesion molecule expression [52]. The selective CYP 2C9 inhibition with 218 
sulfaphenazole has ben reported to result in a significant reduction in MI size after 2 hours of 219 
reperfusion in a rat acute IRI model (fig. 2B) [53]. 220 
Over-expression of endothelial CYP 2C8 has been shown to increase ROS generation and 221 
leukotoxin diols formation, thereby augmenting coronary vasoconstriction and increasing MI size 222 
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[49] [53]. During acute myocardial ischaemia, AA accumulates, leading to increased generation of 223 
20-HETE (20-hydroxy-5,8,11,14-eicosatetraenoic acid) through CYP 4F [54]. 20-HETE acts directly 224 
on cardiomyocytes via the stimulation of NADPH oxidase-derived ROS production, and induces 225 
cardiomyocyte apoptosis. The treatment of endothelial cells with endogenous 20-HETE leads to an 226 
increase in NFB activity and endothelial activation, characterised by the increased expression of 227 
intracellular adhesion molecules and interleukin-8 (IL-8) levels [55] [56] [57]. Inhibition of ROS 228 
production during acute IRI may be more beneficial than a free radical scavenger because such 229 
anti-oxidants must compete with cellular targets to protect tissue from ongoing ROS production. For 230 
example, the administration of cimetidine upon reperfusion has been demonstrated to reduce MI 231 
size, prevent cardiac dysfunction, and attenuate ROS production in the ischaemic region [58]. The 232 
inhibition of 20-HETE with HET0016 (N-hydroxy-N’-(4-butyl-2-methylphenyl)-formamidine) prevents 233 
the activation of inflammatory genes and the endothelial dysfunction [56] [55]. The selective 234 
hydroxylase inhibition with N-methylsulfonyl-12, 12-dibromo-11-enamide (DDMS) 10 minutes before 235 
coronary artery occlusion or 5 minutes before reperfusion was found to reduce MI size [59] [60]. 236 
These data suggest that the inhibition of CYP hydroxylases may induce cardioprotection. However, 237 
further studies are warranted to determine whether pharmacological interventions that disrupt CYP 238 
2C and CYP 4F signalling prevent the development of inflammation associated with acute 239 
myocardial IRI. 240 
 241 
b. Xanthine oxidase 242 
Xanthine oxidoreductase catalyses the oxidation of hypoxanthine to xanthine and the latter to uric 243 
acid as the final steps of purine degradation [61]. Xanthine oxidoreductase has the peculiar property 244 
of existing in two interconvertible forms, xanthine oxidase (XO) and xanthine dehydrogenase (XDH). 245 
XO is formed from XDH under ischaemic conditions and upon myocardial reperfusion [62]. It can 246 
react with purine substrates (hypoxanthine or xanthine) and O2 as the terminal electron acceptor, 247 
thereby exhibiting the ability to generate O-2 and H2O2 [63]. The .OH and O-2 radicals produced by 248 
the enzyme can, in turn, react with cellular proteins and membranes causing cellular injury. XO is 249 
present predominantly in the vascular endothelium in the healthy heart, and has been implicated as 250 
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a primary source of cytotoxic ROS. This is largely based on the observation that allopurinol, an 251 
inhibitor of xanthine oxidoreductase, is as effective as an oxygen radical scavenger in attenuating 252 
the tissue injury associated with acute IRI [64]. Allopurinol has been shown to  decrease MI size 253 
and improved the recovery of LV function following acute IRI [65]. Oxypurinol was found to increase 254 
cardiac output and improve regional LV function after sustained coronary artery occlusion in the 255 
canine heart [66]. Pre-treatment with the XO inhibitor, allopurinol, is effective in inhibiting generation 256 
of ROS during reperfusion and improving recovery of LV function [67].  257 
XO has also been implicated in the leukocyte recruitment that occurs during reperfusion. 258 
Leukocyte-endothelial cell adhesion in post-ischaemic models, and increased neutrophil adhesion 259 
after hypoxia have been reported to be significantly attenuated by XO inhibitors [68]. However, one 260 
problem inherent to the use of allopurinol is that its therapeutic effect is not dose dependent: at 261 
higher doses, it becomes the substrate for XO, which will in turn produce O-2 and thus exacerbate 262 
myocardial damage. ROS generated by XO promote the formation of pro-inflammatory stimuli, 263 
modify the expression of adhesion molecules on the surface of leukocytes and endothelial cells, 264 
and reduce levels of the potent anti-adhesive agent nitric oxide. This latter effect is exacerbated by 265 
the decline in nitric oxide synthase (NOS) activity and oxidation of soluble guanylyl cyclase during 266 
reperfusion, which serves to amplify the intense inflammatory response [69]. Based on these 267 
observations it has been proposed that XO plays an important role in mediating the reperfusion 268 
injury response by promoting the recruitment and activation of leukocytes [67], [70]. 269 
 270 
c. NADPH oxidases 271 
The NADPH oxidases (NOX) family comprises seven members, five NOX and two dual oxidases 272 
(Duox-1 and Duox-2) [71], [72]. They contain six or seven transmembrane spanning domains, 273 
respectively. NADPH oxidase catalyses electron transport from NADPH to molecular oxygen, 274 
thereby producing ROS [73]. Among these isoforms, NOX3 is highly expressed in the cochlea [74]; 275 
NOX1 is expressed in endothelial cells, VSMC and adventitial fibroblasts [75]. NOX2 and NOX 4 276 
are abundantly expressed in cardiomyocytes [72]. NOX5 is located in vascular endothelial cells 277 
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[76], and vascular smooth muscle cells [72], [77] and Duox-1 and Duox-2 are predominantly 278 
expressed in epithelial cells [78].  279 
The proposition that NOX enzymes contribute to acute myocardial IRI is based on two 280 
experimental strands of evidence: (1) the increased expression and activity of NOX in the post-281 
ischaemic myocardium and (2) the attenuation of ROS following pharmacologic inhibition of NOX. 282 
Meischl et al. demonstrated that NOX2 is the predominant isoform that is expressed in 283 
cardiomyocytes, and its expression is upregulated in response to acute IRI [79]. The use of 284 
apocynin and diphenylene iodonium (DPI) (non-specific NOX inhibitors) has been found to reduce 285 
the increase in lipid peroxidation, cell death, and apoptosis after simulated IRI in cardiac cells [80].  286 
NOX can also indirectly cause damage by enhancing the inflammatory response. 287 
Neutrophils that express NOX2 are the primary source of ROS in acute IRI [81], [82]. Some studies 288 
have shown that a phagocyte-like NADPH oxidase is the primary source of O-2 in vascular tissue 289 
[83]. The potential involvement of neutrophils is supported by the observation that the time course 290 
of the inflammatory cell accumulation corresponds with ROS generation and the MI size following 291 
acute IRI. The activation of NOX in neutrophils is triggered via PKC-mediated phosphorylation of 292 
cytosolic p47phox (for neutrophil cytosolic factor 1), which then binds to membrane-associated 293 
gp91phox [84]. ROS generated by NADPH oxidase promote the formation of proinflammatory 294 
stimuli, modify the expression of adhesion molecules on the surface of leukocytes and endothelial 295 
cells, and reduce levels of the potent anti-adhesive agent nitric oxide. Coincident with these 296 
changes, perivascular cells become activated and release another inflammatory mediators such as 297 
tumor necrosis factor alpha (TNF-α) and cytokines [85], [86]. The regulation of different cytokines in 298 
various organs suggest a cell-specific or organ-specific effect of NOX2. However, with respect to 299 
other NOX isoforms, no solid data on their involvement in inflammation and chemotaxis after 300 
reperfusion are available. 301 
 302 
d. Monoamine oxidases 303 
Monoamine oxidases (MAOs) are flavoenzymes located within the mitochondrial outer membrane, 304 
responsible for the oxidative deamination of neurotransmitters and dietary amines [87], [88]. 305 
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Monoamine oxidase A (MAO-A) and B (MAO-B) share 70% amino acid identity, and both contain a 306 
covalently bound FAD cofactor attached to an enzyme cysteine via the 8α-methylene of the 307 
isoalloxazine ring [89]. This flavin moiety is the only redox-dependent factor necessary for their 308 
activity. The reaction of oxidative deamination occurs in several steps, ultimately resulting in the 309 
formation of the aldehyde from the corresponding amine, ammonia and H2O2. MAOs catalyse 310 
oxidative deamination of several monoamines (serotonin [5-hydroxytryptamine (5-HT)], 311 
noradrenaline, dopamine), resulting in significant ROS production [88]. Recent studies suggest that 312 
MAOs contribute to increasing H2O2 production and catecholamine release in the early reperfusion 313 
period (5-15 minutes) [90]. MAO-A generated H2O2 in acute IRI induces sphingosine kinase 314 
inhibition, ceramide accumulation, and sphingosine-1-phosphate degradation in cardiomyocytes 315 
thereby leading to mitochondria-mediated apoptosis in H9c2 cells [91]. Currently, efforts are 316 
underway to investigate the mechanisms underlying the protective effect of MAO inhibitors 317 
(selegiline, D-Deprenyl), and the roles of MAO in the setting of acute IRI [92], [93]. 318 
 319 
e. Mitochondrial electron transport chain 320 
Mitochondria have been implicated as a major source of ROS in acute myocardial IRI. The rapid 321 
movement of electrons through the electron transport chain (ETC) of the inner mitochondrial 322 
membrane can result in the leakage of electrons, which form O-2 via univalent reduction of O2. All of 323 
the ETC complexes have been implicated as both sources and targets of the ROS generated during 324 
myocardial IRI, although most evidence supports a role for complexes I and III.  325 
Mitochondrial complex I is viewed as a major contributor of ROS [11]. Oxidative impairment 326 
of complex I is detected in rat models of acute myocardial IRI [94]. Mitochondrial complex I has two 327 
catalytically and structurally distinct forms; one the fully competent, active A-form and the other, the 328 
deactivated, D-form. The reversible D-form of complex I predominates under ischaemic conditions, 329 
produces O-2 and H2O2, and may potentially increase the susceptibility of mitochondria to oxidative 330 
damage [95]. Reperfusion also induces disruption of complex II; Chen et al. found that ADP-331 
stimulated state 3 respiration driven by succinate was 50% impaired in mitochondria from 332 
reperfused hearts, a finding which was attributed to the impairment of complex II. The 333 
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deglutathionylation of complex II predisposes the 70-kDa flavin binding subunit to oxidative stress 334 
induced by ROS during reperfusion injury [96].  335 
Complex III is also considered an important source for mitochondrial ROS production in 336 
reperfused hearts. In the ischaemic heart, mitochondrial complex activity is reduced by 22% 337 
compared with healthy hearts. Increase unstable semiquinone radical (•Q-), is attributed to be the 338 
source of O-2. Mammalian complex III contains bound cardiolipin molecules that are essential for 339 
the catalytic function. The impairment of complex III activity due to the ROS-induced cardiolipin 340 
oxidative damage may increase the electron leak from the electron transport chain, generating 341 
more O-2 and perpetuating a cycle of oxygen radical-induced damage, which ultimately leads to an 342 
increase in MI size [97]. The burst of ROS from mitochondrial complexes induce the oxidation of 343 
cholesterol and the production of oxysterols. Oxyesterols can induce interleukin-1 beta (IL-1) 344 
secretion in vascular endothelial cells and, consequently, the expression of adhesion molecules 345 
necessary for the recruitment of immune cells [98]. Additionally, CYPs have been found in the 346 
mitochondria of diverse animal species. Mitochondrial CYPs are proteins bound to the inner 347 
membrane, and receive electrons for monooxygenation reaction from NADPH via adrenodoxin and 348 
NADPH-adrenodoxin reductase [99]. Mitochondrial CYP catalyses the conversion of cholesterol in 349 
pregnenolone and play essential roles in cholesterol homeostasis and steroid hormone biosynthesis 350 
[100]. Recently, it has been shown that myocardial reperfusion induces mitochondrial cholesterol 351 
accumulation. Peradis et al. showed that acute myocardial IRI produces high cholesterol and 352 
oxysterol concentrations in the matrix and a simultaneous decrease in mitochondrial membrane 353 
fluidity related to oxidative stress [101]. In this setting, the oxysterols 5, 6-epoxycholesterol, 7-354 
hydroxycholesterol, 7-ketocholesterol and 25-hydroxycholesterol exert a potent cytotoxic effect by 355 
their ability to induce inflammatory effects [102].  356 
Liu et al. have demonstrated that the oxysterol, 25-hydroxycholesterol, enhances IL-8 357 
production [103]. It is noteworthy to mention that IL-8 is a cytokine which might play an important 358 
role in the recruitment of T lymphocytes and monocytes into the arterial subendothelial space [104]. 359 
As summarised in figure 2C, by inhibiting cholesterol uptake into mitochondria at reperfusion with 360 
4’-chlorodiazepam, the accumulation of oxysterols can decrease the inflammatory response and 361 
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induce cardioprotection. Further investigation is required to explore in more detail the relationship 362 
between oxysterols and inflammation in the setting of acute IRI (fig. 2C). 363 
 364 
f. UPR-regulated oxidative protein folding machinery in the SR/ER  365 
The cardiomyocyte sarco/endoplasmic reticulum (SR/ER) is an intracellular organelle specialising in 366 
the regulation of Ca2+ fluxes and different oxidative functions. There is increasing evidence that 367 
SR/ER stress plays a crucial role in IRI-induced cell dysfunction. Oxygen starvation during 368 
ischaemia and ROS and Ca2+ overload during reperfusion results in SR/ER stress and the 369 
activation of the pro-inflammatory pathway. 370 
 Mitochondria and SR/ER are in close apposition and the interface, commonly known as the 371 
mitochondrial-associated SR/ER membrane, is believed to act as the focal point for signaling [105]. 372 
During acute myocardial IRI, both the release and uptake of calcium from the SR/ER are 373 
dysregulated, resulting in enhanced Ca2+ release [46]. Much of the calcium is taken up by the 374 
mitochondria and Ca2+ within the mitochondria, and induces the superoxide formation. Several in 375 
vitro studies have demonstrated that the calcium pump on the SR/ER membrane is quite sensitive 376 
to oxidative stress and the fact that the SR/ER contains a large amount of lipids and that it produces 377 
ROS could also make this organelle very easily damaged by ROS. This vicious cycle of Ca2+ 378 
leakage, calcium overload and ROS generation inhibits cardiac contractility.  379 
SR/ER stress initiates the activation of the unfolded protein response (UPR). The UPR 380 
increases the capacity of the protein folding machinery resulting in the production of more oxidative 381 
equivalents, and future deteriorating the redox state. UPR can induce TNF- production in 382 
response to ER stress through IRE1 (inositol-requiring transmembrane kinase and endonuclease 383 
1) and the ER-localised protein kinase PERK pathway [106] [107]. PERK-induced translational 384 
arrest leads to the loss of IB, thereby activating NFB [108]. In addition, the phosphorylation of 385 
IRE1 in response to stress induces a conformational change in its cytosolic domain, which can 386 
then bind to the adaptor protein, TNF--receptor-associated factor 2 (TRAF2), the receptor that can 387 
activate canonical NFB JNK MAPK signaling pathway [109]. The efflux of Ca2+ from the SR/ER 388 
generates ROS and NFB activation and gene expression that drive inflammation [110] [111]. NFB 389 
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induction by SR/ER stress is prevented by pre-incubation of cells with intracellular Ca2+ chelators, 390 
suggesting that Ca2+ release precedes ROS formation in the NFB-mediated SR/ER-nuclear signal 391 
transduction pathway [112]. Several studies have demonstrated that hypoxia/reoxygenation is 392 
sufficient to induce SR/ER stress [113] [114]. NFB acts as a link between SR/ER stress and 393 
inflammation after hypoxia/reoxygenation. NFB inhibitors can protect cells against IRI by 394 
selectively inhibiting the translocation of NFB to the nucleus. In this regard, Wu et al. have shown 395 
that SN50 can effectively can reduce damage to cardiomyocyte after reoxygenation [107].  396 
 397 
g. Nitric oxide synthase  398 
Neuronal nitric oxide synthase (nNOS), inducible NOS (iNOS) and endothelial NOS (eNOS) 399 
generate NO• via the oxidation of L-arginine. NOS isoforms contain both an oxygenase and 400 
reductase domain. The reductase domain contains flavin adenine dinucleotide (FAD) and flavin 401 
mononucleotide (FMN), and binds NADPH, while the oxygenase domain contains heme and 402 
tetrahydrobiopterin (BH4), and binds arginine. Uncoupling of NOS results in the loss of NO• 403 
production, and O-2 production. A recent study by Lin et al. demonstrated that phosphorylation of 404 
eNOS at threonine 497 mediated the switch between NO• production to superoxide generation 405 
[115].  406 
However, the most prominent cause of NOS uncoupling is the loss of the critical NOS co-factor, 407 
BH4, either by oxidation or decreased expression of the recycling enzyme dihydrofolate reductase 408 
(DHFR) [116]. BH4 depletion is involved in both endothelial and cardiomyocyte dysfunction in 409 
hearts following acute IRI. Myocardial levels of BH4 levels have been shown to be markedly 410 
decreased after 60 minutes of reperfusion, and NOS uncoupling occurs with the increase in 411 
myocardial O-2 formation. When electron flow is uncoupled from arginine oxidation, the reduced O-2 412 
is released from the heme as O-2.  413 
Endothelial NOS is mostly expressed in endothelial cells, cardiomyocytes and platelets. eNOS 414 
synthesises NO• in a pulsatile manner with eNOS activity markedly increasing when intracellular 415 
Ca2+ is increased [117]. Recent evidence has indicated that reversing NOS uncoupling in acute 416 
myocardial IRI may be a therapeutic strategy [118]. Also, several studies have demonstrated that 417 
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low levels of heart BH4 result in myocardial inflammation. Zsuzsnna et al. demonstrated that 418 
plasma BH4, TNF- and IL-6 levels showed an inverse correlation with the absolute values of LV 419 
function, suggesting that oxidative stress and inflammation may be responsible for LV systolic 420 
dysfunction in IRI [119]. However, further studies are warranted to determine whether NOS 421 
uncoupling induces inflammation associated with acute myocardial IRI. 422 
  423 
5. Dysregulation of myocardial anti-oxidant pathways during acute myocardial IRI 424 
Myocardial reperfusion increases the production of ROS and undermines the anti-oxidant defence 425 
in heart tissue, cause a redox imbalance. Myocardial anti-oxidants can be divided into the 426 
endogenous anti-oxidant system and exogenous anti-oxidants. The first line of endogenous anti-427 
oxidants include anti-oxidant enzymes such as superoxide dismutase (SOD), catalase and 428 
glutathione peroxidase, and non-enzymatic anti-oxidants including ∝-tocopherol (vitamin E), 429 
ubiqinol or coenzyme Q10 (Q10), ascorbic acid (vitamin C) and glutathione (GSH) amongst others 430 
[120], [121]. In the setting of acute IRI, levels of myocardial non-enzymatic anti-oxidants are 431 
suppressed. Total myocardium ascorbate, Q10, and glutathione levels decline as a function of the 432 
length of reperfusion period, and the administration of exogenous anti-oxidants can mediate 433 
cardioprotection [122]. 434 
The presence of a higher glutathione peroxidase (GPx) activity is vital for the heart to 435 
survive the attack of ROS produced in the reperfused myocardium. GPx catalyses the peroxidation 436 
of H2O2 in the presence of reduced glutathione (GSH) to form H2O and oxidised glutathione 437 
(GSSG). Cardiomyocytes contain a GSH redox cycle, in which GPx reaction accepts peroxides and 438 
peroxide-derived alkoxyl and peroxyl radicals as substrates. Glutathione is a tripeptide, γ-L-439 
glutamyl-L-cysteinylglycine, present in the heart at 1-10mM concentrations [123]. GSH reductase 440 
replenishes the loss of GSH using NADPH as a donor for reducing equivalents, however, the 441 
oxidative stress during reperfusion results in the depletion of myocardial GSH and NADPH and 442 
efflux of GSSG [124], [125]. Yoshida et, al, have demonstrated that the GPx knockout (KO) mouse 443 
hearts are more susceptible to acute IRI [126].  444 
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The transcription factor Nrf2 is a master regulator of a spectrum of genes related to GSH 445 
metabolism via the anti-oxidant responsive element (ARE) on target genes, and also plays a role in 446 
xenobiotic detoxification and proteome maintenance [127], [128]. In response to oxidative stress, 447 
Nrf2 dissociates from the inhibitory regulator Keap1, and translocates to the nucleus to induce the 448 
transcription of anti-oxidant genes GSH synthetase, glutathione-S-transferase, GSH peroxidase, 449 
GHS reductase and NADPH quinone oxidoreductase [127], [129]. The stimulation of Nrf2 is 450 
connected with activation of the PI3K/Akt kinase pathway which was shown to play a role in the 451 
mechanism of increased myocardial tolerance to acute IRI and reduction of oxidative stress [129] , 452 
[130].  453 
Oxidative stress depolarises mitochondria by causing lipid peroxidation, which further leads 454 
to mitochondrial dysfunction. Q10 is a well-characterized electron carrier of the respiratory chain, 455 
which is mainly localised in the inner mitochondrial membrane where it serves as a highly mobile 456 
carrier of electrons and protons between the flavoproteins and the cytochrome system [131]. 457 
Because of its ability to transfer electrons, it acts as an anti-oxidant. Q10 must be reduced to 458 
ubiquinol denoted quinol (QH2) to yield its maximum anti-oxidative function. In its reduced form 459 
(ubiquinol), the Q10 molecule holds electrons loosely and will quite easily give up one or two 460 
electrons to neutralise free radicals [131], [132]. The anti-oxidant properties of Q10 and its locatoin 461 
within the mitochondria make it an potential therapeutic target for the treatment of acute IRI [133]. In 462 
conditions of high oxidative stress, the rate of inactivation of NO to peroxynitrite by superoxide 463 
anions may be reduced by Q10, and reduce the products of lipid peroxidation levels [134]. 464 
Coenzyme Q10 also decreases blood viscosity, improves coronary vasodilation by protecting the 465 
endothelial function in patients with ischaemic heart disease [135], [136]. It decreases inflammatory 466 
cytokines and prevents the hyperglycemia-induced endothelial cell damage, monocyte adhesion 467 
and evolution of atherosclerotic lesions in diabetic patients [137].  468 
SOD is an enzyme that converts superoxide anion to hydrogen peroxide, which is 469 
subsequently converted to water by catalase [138]. It protects against oxidative stress and has 470 
three isoforms: Cu-Zn SOD (SOD1), located in the cytosol; Mn-SOD (SOD2), located in the 471 
mitochondrial matrix; and extracellular SOD (SOD3) [139]. Anti-oxidant enzymes have specific 472 
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targets, and they function as a sensor of specific types of ROS. For instance catalase and 473 
peroxiredoxins target H2O2 whereas SODs only target superoxide. Inadequate delivery of anti-474 
oxidants to their target sites within the cell where ROS are produced may be the cause of the 475 
controversial results obtained so far because these enzymes can detoxify ROS only at the sites to 476 
which they are delivered. 477 
Mammals have seven sirtuins (SIRT1-7) that possess NAD+-dependent deacetylase, 478 
deacetylase, and ADP-ribosyltransferase activities. Sirtuins are found in different subcellular 479 
locations, including the nucleus (SIRT1, SIRT6, and SIRT7), cytosol (SIRT2), and mitochondria 480 
(SIRT3, SIRT4, SIRT5) [140]. SIRT3 deacetylates several lysine residues of MnSOD thereby 481 
increasing MnSOD activity and detoxification of superoxide radicals. The dependence of SIRT3 on 482 
the NAD+/NAD ratio may determine the function of SIRT3 [141]. During myocardial reperfusion, 483 
mitochondrial NAD+ levels decrease [142], suggesting that SIRT3 activity may be compromised 484 
during reperfusion and may contribute to the extent of acute IRI. In the Langendorff model, seven 485 
months old SIRT3+/- mice showed impaired recovery of cardiac function and larger MI size following 486 
25 minutes of ischaemia [143]. SIRT6 reduced oxidative stress injury via an AMPK-dependent 487 
pathway. Under normal nutrients conditions, SIRT6 binds to the promoters of glycolytic genes, 488 
keeps histone H3K9 acetylation levels low, and directs glucose into the mitochondria for efficient 489 
ATP production and away for glycolysis. SIRT6 deficiency also significantly reduced both the 490 
expression and activity of SOD and catalase in ischaemic hearts. SIRT6-/- mice showed more 491 
severe acute myocardial IRI resulted from the collapse of the endogenous ROS-scavenging 492 
enzyme system, which induces ROS accumulation and stronger oxidative stress [144]. Oxidative 493 
stress activates FOXOs in cardiomyocytes mediated by AMPK and sirtuins (SIRT1 and SIRT2). 494 
SIRT1 protects the heart from acute IRI through upregulation of anti-oxidants and downregulation of 495 
proapoptotic molecules. FOXO promotes cardiomyocytes survival upon induction by oxidative 496 
stress. SIRT1 enhances transcription factor of some FOXO target genes. Cells lacking Sirt3 497 
exhibited altered metabolism, including a significant increase in mitochondrial superoxide levels 498 
when exposed to cellular stress [140]. 499 
 500 
 19 
6. The acute-phase response: tissue damage, inflammatory response, and more ROS 501 
Myocardial reperfusion is associated with an inflammatory response, which ultimately leads to 502 
healing and scar formation. Acute myocardial IRI involves degradation of extracellular matrix 503 
components by metalloproteinases (MMPs), oxidative stress, apoptosis and activation of 504 
complement system. The inflammatory response in the reperfused myocardium is related to the 505 
coordinated activation of a series of cytokine and adhesion molecule genes resulting in loss of 506 
barrier integrity and release of ROS into the extracellular matrix. It increases expression of adhesion 507 
molecules; acts as a chemoattractant for neutrophils, initiating their recruitment; activates the 508 
complement cascade and promotes apoptotic cell death. 509 
The production of ROS peaks during the first 2–10 minutes of reperfusion after coronary 510 
artery occlusion and has been considered to be the first stimuli from neutrophils that invade the 511 
ischaemic region [50]. Necrotic cell death triggers release of cell contents with some of the 512 
endogenous compounds being able to activate immune cells. NF-κB is activated by various local 513 
substances including ROS [145], [146]. Upon activation, NF-κB stimulates inflammatory and 514 
immune responses. This factor also triggers gene expression of pro-inflammatory cytokines, such 515 
as TNF-α and interleukins, initiating an inflammatory response [147]. Upregulation of chemokines 516 
and cytokines results in extravasation of activated blood-derived cells into the infarcted area. 517 
Platelets are the first cells recruited to the site of infarct area, as a result of the coagulation process. 518 
Subsequently, various subsets of leukocytes infiltrate the myocardium and remove the dead cells 519 
and matrix debris [148]. During the adhesion process, the activated platelets release adhesion 520 
proteins (fibrinogen, fibronectin, P-selectin, glycoprotein IIb/IIIa), growth factors (PDGF), endothelial 521 
growth factor, fibroblast growth factor, chemokines, epithelial neutrophil-activating, cytokine-like 522 
factors (interleukins) and coagulation factors into the local environment, thereby altering 523 
chemotactic, adhesive and proteolytic properties of endothelial cells and supporting chemotaxis 524 
adhesion and transmigration of monocytes to the site of inflammation [149],  [150]. Concomitantly, 525 
intercellular tight junctions are compromised, which leads to endothelial barrier dysfunction and 526 
increased vascular permeability. Also, platelets are capable of initiating complement activation and 527 
may play a role in localising the inflammatory response to the area of injury [151]. 528 
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Neutrophils arrive on the scene very early after the tissue damage (4 hours after 529 
reperfusion) [152]. Their principal role appears to be mediated by adhesive interactions with 530 
activated endothelial cells of the vessels. Neutrophil inﬁltration into the infarcted area implies the 531 
generation of ROS and proteolytic enzymes contributing to the clearance of dead cells and debris 532 
from the infarcted area [153]. Also, they may express mediators capable of amplifying cell 533 
recruitment. Experiments have suggested that the mechanism of neutrophil-cardiomyocyte 534 
adhesion is dependent on CD18 integrin activation on neutrophils and expression of ICAM-1, one of 535 
the primary ligands for the CD18 integrins. Neutrophils block capillaries preventing reperfusion of 536 
the tissue, which leads to tissue necrosis and an exacerbated immune response. In vitro the 537 
mechanism of neutrophil–cardiomyocyte injury was shown to be strictly dependent on CD18 integrin 538 
activation and ICAM-1 expression by damaged cardiac cells. A neutrophil NADPH oxidase inhibitor 539 
and a monoclonal antibody against the neutrophil CD18 adhesion molecule markedly reduced 540 
oxygen radical levels, in addition to reducing MI size and no-reflow [81]. 541 
 542 
7. Physiological consequences of the inflammatory response 543 
7.1. No-reflow 544 
No-reflow (NR) or microvascular obstruction is the term used to describe the inadequate perfusion 545 
of a given coronary segment without angiographic evidence of epicardial vessel obstruction. 546 
Between 2 minutes and 8 hours of reperfusion, the area of NR increases 3-fold with most of the 547 
expansion occurring within the first 1–2 h of reperfusion [154]. The factors associated with the 548 
establishment of NR include endothelial dysfunction, compression of capillaries by swollen 549 
myocytes, alteration of the vasoregulation pathways, epicardial spasm, mechanical obstruction from 550 
embolization, extrinsic coagulation pathways, leukocyte adherence, microvascular ischaemia, 551 
oedema and vasoconstriction mediators [155], [156]. Endothelial cell injury occurs in approximately 552 
20% of vessels after 60 minutes of reperfusion, and in 40% of vessels at 20–80 minutes of 553 
reperfusion. Indeed, initial reports showed tightly packed erythrocytes and endothelial gaps plugged 554 
by platelet and fibrin thrombi with many extravascular red blood cells in capillaries from hearts 555 
reperfused only during 20 minutes [157]. Platelet aggregates or fibrin clots could be implicated as 556 
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factors responsible for obstructing capillaries. Besides mechanical obstruction, leukocytes release a 557 
variety of pro-inflammatory cytokines that may contribute to NR by recruiting additional inflammatory 558 
cells enhancing leukocyte adhesion to the endothelium, altering coagulation or increasing 559 
vasoconstriction (Figure 3).   560 
 561 
7.2. Post-MI left ventricular remodeling 562 
The inflammatory reaction following AMI controbutes to cardiac structural remodelling, followed by 563 
scar formation at the site of infarction as well as changes in the non-infarcted myocardium, including 564 
interstitial fibrosis and vascular remodelling. The term remodelling was proposed to characterize the 565 
response of remote myocardium to regional infarction and the progression from acute myocardial 566 
infarction to chronic heart failure.  567 
There is growing recognition and experimental evidence that oxidative stress-mediated and 568 
inflammation regulate the pathogenesis of myocardial remodelling following AMI. Circulating 569 
neutrophils and macrophages arrive at the infarct site after reperfusion. They contribute to the 570 
proteolytic digestion and phagocytosis of the infarcted tissue, respectively. The inflammatory 571 
response peaks at weeks 1 and 2 post-MI. Collagen synthesis, preferentially mediated by 572 
myofibroblasts, is induced in response to different stimuli; these include mechanical stress, 573 
vasoactive factors such as angiotensin II and growth factors such as transforming growth factor-β 574 
(TGF-β), which can act directly or through the up-regulation of connective tissue growth factor 575 
(CTGF). The fibrogenic component, which substitutes for lost parenchymal cells, follows the initial 576 
phase of collagen degradation. Collagen degradation is mediated by a family of zinc-containing 577 
endoproteinases- matrix metalloproteinases. These enzymes are found in the heart at low levels in 578 
normal conditions but can be up-regulated after MI in response to inflammatory cytokines and TGF-579 
β [158], [159]. 580 
 581 
7. Therapeutic targeting of ROS and inflammation 582 
It is not surprising that research over recent years has focused on anti-oxidants as a potential 583 
therapy in the setting of acute myocardial IRI [160]. Although many initial studies in cells or animal 584 
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models have been successful, clinical trials have produced disappointing results, owing to 585 
differences between animal models and human disease, the inability of the agents to reach the 586 
important cellular locations, and the stage and cell-specific regulation of oxidant and anti-oxidant 587 
pathways.  588 
According to previously discussed data, it may be preferable to adopt a pharmacological 589 
strategy that decreases mitochondrial oxidative damage to reduce acute IRI. The relatively poor 590 
efficacy of conventional anti-oxidants may be the consequence of their low penetrance to the 591 
mitochondrial matrix, which not only is the main site of ROS production but also suffers from 592 
oxidative stress. Pretreatment with or infusion of Q10 soon after coronary artery ligation has been 593 
shown to reduce MI size and preserve systolic function in rat models of AMI [161]. Q10 prevents the 594 
peroxidation of the cell membrane and subcellular lipids, which occurs during acute IRI [162]. Q10 595 
also regulates the release of nitric oxide, and it creates endothelial regeneration and 596 
immunostimulation [163], [164] and recovery of LV function after AMI [165]. However, lipophilic 597 
cations have a disadvantage. Since the charge accumulation into the matrix leads to mitochondrial 598 
membrane depolarisation, at the concentration greater than 10mM, toxicity has been observed, and 599 
the low solubility of ubiquinone in water makes it difficult to use in vitro, and animals must be fed 600 
Q10-enriched diets for several weeks to increase levels in subsequently isolated mitochondria. More 601 
hydrosoluble molecules than ubiquinone have been developed and tested in different diseases. 602 
Therefore, to manipulate mitochondrial Q10 or ubiquinone Kelso et al. synthesised a ubiquinone 603 
analogue selectively targeted to mitochondria by the addition of a lipophilic triphenylphosphonium 604 
cation, mitoquinone (MitoQ) [166]. The lead compound, MitoQ, consists of a targeting lipophilic 605 
triphenyl phosphonium (TPP) cation linked to a ubiquinone moiety. Using this model, it was 606 
demonstrated that the administration of MitoQ before the onset of ischaemia reduced oxidative 607 
damage and severity of acute IRI, thereby providing functional protection to the heart [167]. 608 
Myocardial treatment with MitoQ prevented the initial damage and the activation of the inflammatory 609 
response. MitoQ also can reduce Ca2+ overload and mPTP opening [168].These findings suggest 610 
that mitochondria-targeted therapies designed to minimise mitochondrial oxidative damage may 611 
decrease post-reperfusion dysfunction. 612 
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A growing number of studies suggest that the compound, Szeto-Schiller-31 (SS-31) 613 
peptide, also known as Bendavia may be cardioprotective. SS-peptides were developed by Szeto 614 
and Schiller and constitute a series of 4 small, cell-permeable anti-oxidant compounds with three 615 
positive charges in homeostatic pH conditions [169]. The SS-31 peptide can scavenge H2O2 and 616 
ONOO• and inhibit lipid peroxidation, anti-oxidant actions attributed to a tyrosine or dimethyl 617 
tyrosine residue in their structure, the latter of the two being more efficient concerning ROS 618 
scavenging. In a recent study, Liu et al. showed that SS-31 prevented swelling of mitochondria and 619 
protected mitochondrial cristae in both endothelial and epithelial cells. It was associated with a 620 
significantly reduced loss of peritubular capillaries and cortical arterioles, interstitial inflammation, 621 
and fibrosis four weeks after ischaemia [170]. However, the EMBRACE-MI clinicla study failed to 622 
demonstrate a reduction in MI size in AMI patients administered Bendavia prior to reperfusion [171]. 623 
Another strategy to preserve redox balance and maintain mitochondrial function is the 624 
induction of endogenous anti-oxidants Trolox (6-hydroxy-2,5,7,8- tetramethylchroman-2-carboxylic 625 
acid) is a water-soluble analogue of the free radical scavenger α-tocopherol. Due to its enhanced 626 
water solubility, Trolox may function more rapidly during acute oxidative stress, while α-tocopherol 627 
requires several days of pretreatment to exhibit anti-oxidant benefits. Du et al. demonstrated that 628 
chitosan nanoparticles, when used as drug carriers for the delivery of Trolox, exerted a protective 629 
effect against hypoxia-mediated oxidative stress and can block the mitochondria-dependent 630 
apoptotic pathway through upregulation of Bcl-2 expression and inhibition of Bax activation and 631 
Caspase-3 expression [172].  632 
Recently, the use of natural molecules with specific physicochemical properties has 633 
emerged. Vitamin E, C, A and other agents in complementary and alternative medicine have been 634 
studied and whereas some had protective effects in animal models, although none of them has 635 
demonstrated clear benefit for patients. Curcumin is the major active component of turmeric, a 636 
yellow compound isolated from the plant Curcuma longa, used for centuries in traditional medicine 637 
[173]. This molecule has shown therapeutic potential against a wide range of diseases, mainly due 638 
to its anti-inflammatory [174]. Curcumin exerts both direct and indirect anti-oxidant effects by 639 
scavenging ROS. Also, it has been shown that early treatment with curcumin attenuates cardiac 640 
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hypertrophy and remodelling. Curcumin might have therapeutic potential in the treatment of heart 641 
disease by attenuating oxidative stress-related events as cardiac remodelling, mitochondrial 642 
dysfunction and cell death [175]. 643 
The phosphorylated form of GSK-3 correlates with the activity of cardioprotection. Via 644 
inhibition of GSK-3, protective signalling pathways act on the end effector mitocohndrial 645 
permeability transition pore; that is, they prevent the induction of the mitochondrial permeability 646 
transition, restore mitochondrial membrane potential, and decrease ROS production. The synthetic 647 
17β-aminoestrogen Prolame [17β-(3-hydroxy-1-propylamino)- 1,3,5(10)-estratrien-3-ol)] is an 648 
estradiol analogue in which the C17 position of the steroid nucleus is substituted by an amino-649 
alcohol side chain-NH-(CH2)3-OH with three methylenes groups. Prolame might diminish the no-650 
reflow phenomenon and provide cardioprotection in rats with AMI followed by reperfusion [156]. 651 
Initial success has been established in preclinical models of acute myocardial IRI for a 652 
handful of therapeutics that target neutrophils [176] [177]. A monoclonal antibody targeted against 653 
the CD11/CD18 integrin showed promising results in animal models, but clinical trials failed to show 654 
a significant reduction in MI size [178].  655 
 656 
CONCLUSION 657 
Following AMI, the production of ROS and the ensuing inflammatory response are critical 658 
determinants of myocardial injury, cardiomyocyte death and subsequent LV remodelling in the 659 
setting of acute IRI, providing therapeutic targets for cardioprotection. However, a number of anti-660 
oxidants have been tested in the setting of AMI, and despite being positive in the experimental 661 
setting, most have failed in the clinical setting. The reasons for this are unclear, but may relate to 662 
the inability to achieve sufficent concentrations of anti-oxidant at the site of ROS production. 663 
Proteomic and metabolomic approaches may help in discover novel pathways underliyng the redox-664 
mediated inflammation progression. Overcoming these issues would greatly enhance the 665 
development of successful therapies to combat oxidative stress, inflammation and cell damage, 666 
providing new treatments for AMI patients. 667 
 668 
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Figure 1. Formation of different ROS and reactive nitrogen species from dioxygen. 1255 
ischaemia/reperfusion injury. Dioxygen (O2) is shown to undergo reduction to form superoxide (O-2). 1256 
Superoxide is shown to dismutate to form hydrogen peroxide (H2O2), and hydrogen peroxide is 1257 
shown to interact with Fe2+ and to form hydroxyl radical (OH) via the Fenton reaction. Superoxide 1258 
dismutase (SOD), nitrogen monoxide (NO), peroxynitrite (ONOO). 1259 
 1260 
Figure 2. Schematic representation of (A) the sources of reactive oxygen species during acute 1261 
myocardial ischaemia/reperfusion injury. (B) During acute myocardial ischaemia, AA accumulates, 1262 
leading increased generation of 20-HETE through CYP 4F. 20-HETE acts directly via the 1263 
stimulation of NADPH oxidase-derived ROS production and induces NFB activation. (C) 1264 
Myocardial reperfusion generates accumulation of cholesterol into mitochondria. This induces the 1265 
formation of oxysterols, which can induce IL-1 and IL-8 secretion.  1266 
Cytochrome P-450 (CYP), xanthine oxidase, NADPH oxidase, monoamine oxidases (MAO), 1267 
sarco/endoplasmic reticulumun (SR/ES), nitric oxide synthase (NOS), arachidonic acid (AA), 20-1268 
HETE (20-hydroxy-5,8,11,14-eicosatetraenoic acid), EETs (epoxyeicosatrienoic acids), NFB 1269 
(nuclear factor kappa-light-chain-enhancer of activated B cells), N-methylsulfonyl-12, 12-dibromo-1270 
11-enamide (DDMS), HET0016 (N-hydroxy-N’-(4-butyl-2-methylphenyl)-formamidine), cholesterol 1271 
(chol), IL-1 (interleukin-1 beta), IL-8 (interleukin-8), IRI (Ischaemia/Reperfusion Injury), ROS 1272 
(reactive oxygen species). 1273 
 1274 
Figure 3. No-reflow following acute myocardial ischaemia/reperfusion injury. (A) Example of infact 1275 
assessment using triphenyl tetrazolium chloride (TTC) staining (B) Example of no-reflow by 1276 
transillumination of Microfil-perfused coronary; and (C) Schematic diagram demonstrating the 1277 
multiple etiologies of no-reflow in the reperfused coroanry artery.  1278 
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